Humanity is entering unprecedented technological and socio-cultural changes that will lead to the advent of a new paradigm with major structural changes, shifting even further from digital to hybrid virtual transformation.
We aspire to pave the brave new world by facilitating and nurturing the new business and especially those in Research with deep tech innovation disruptions and where applicable, digital twin technologies in various verticals while we will enable our members to take advantage of AI-solutions.
By establishing the Greek Scientists Society we wish to develop the necessary tools and provide the necessary means for the Greek and Cypriot Scientists to successfully implement their Research and then market their results.
Although we are field agnostic and we invite Scientists from all disciplines, we focus at first on the Biomed sector with the establishment of the Hellenic Biomed Network and on the IT sector with the Hellenic Infotech Network
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Prof. Phoebe Koundouri is a world-renowned environmental economics professor and global leader in sustainable development. She is widely recognized as a pioneer in innovative, human-centric, interdisciplinary systems for the sustainable interaction between nature, society, and the economy. She is listed in the most-cited women economists in the world, included within the official Stanford University list of the Top 2 % of world scientists, with 15 published books and more than 500 published peer reviewed scientific articles, book chapters, research and policy reports.
Prof. Koundouri is an elected fellow of the World Academy of Art & Science and the President of the European Association of Environmental and Natural Resource Economists (EAERE), the largest scientific association in the field, with more than 1000 member institutions, from more than 55 countries.
John S. Baras is a Distinguished University Professor, holding the Lockheed Martin Chair in Systems Engineering and a Permanent Joint Appointment with the Institute for Systems Research (ISR) and the ECE Department at the University of Maryland College Park (UMD).
He received his Ph.D. degree in Applied Mathematics from Harvard University, in 1973, and he has been with UMD since then. From 1985 to 1991, he was the Founding Director of the ISR. Since 1992, he has been the Director of the Maryland Center for Hybrid Networks (HYNET), which he co-founded.
He is a Fellow of IEEE (Life), SIAM, AAAS, NAI, IFAC, AMS, AIAA, Member of the National Academy of Inventors (NAI) and a Foreign Member of the Royal Swedish Academy of Engineering Sciences (IVA).
His research interests include systems, autonomy, machine learning, artificial intelligence, communication networks, robotics, computing systems, formal methods and logic, network security and trust, model-based systems engineering.
Endowed Chair Professor in Wireless Telecommunications and Director of the Digital Technology Center at University of Minnesota
Area of expertise: Wireless Communications and Networking, Statistical Signal Processing, and Sensor Networks
General interests span the areas of communications, networking and signal processing, estimation and detection theory, time-series analysis, and system identification. Areas of past research have included (poly)spectral analysis, wavelets, cyclostationary, and non-Gaussian signal processing with applications to sensor arrays and image processing. Current research focuses on complex-field and network coding, cooperative wireless communications, cognitive radios, cross-layer designs, mobile ad hoc networks, and wireless sensor networks.
Theodoros Evgeniou is Professor of Decision Sciences and Technology Management at INSEAD and director of the INSEAD Executive Education program on Transforming your Business with AI. He is a World Economic Forum Academic Partner for Artificial Intelligence, a member of the OECD Network of Experts on AI, and an advisor for the BCG Henderson Institute.
He has been working on Machine Learning and AI for the past 25 years, on areas ranging from AI innovations for business process optimization and improving decisions in Marketing and Finance, to responsible AI and digital regulations, as well as on new Machine Learning methods.
His research has appeared in leading journals, such as in Science Magazine, Nature Machine Intelligence, Machine Learning, Lancet Digital Health, Journal of Machine Learning Research, Management Science, Marketing Science, Harvard Business Review magazine, and others.
He has received four degrees from MIT.
Sophia Karagiannis is Professor of Translational Cancer Immunology and Immunotherapy at King’s College London.
She received BA and MS degrees at Rutgers University, USA, under scholarship and teaching assistantship awards, and a PhD at King’s College London in Biochemistry under SERC and SmithKline Beecham-funded scholarships. She has developed several immunotherapeutic strategies for tissue cancers and inflammatory diseases in academic and biotechnology environments in London and in Cambridge, UK. Her cancer antibody discovery group at King’s College London specialises in dissecting B cell and antibody immune responses and in designing therapeutic monoclonal antibodies and derivatives with main focus on skin, ovarian and breast cancers.
Her group is the first internationally to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical studies and launched a Phase I clinical trial, where a first-in-class therapeutic antibody was tested in patients with cancer. Karagiannis is founder of Epsilogen Ltd (formerly IGEM Therapeutics Ltd.), the first immuno-oncology company dedicated to developing IgE therapeutic agents for cancer.
George P. Chrousos, MD, ScD born in Patras, Greece, is a Greek-American pediatrician, endocrinologist, neurobiologist and one of the world’s foremost medical clinical researchers. He serves as Professor of Pediatrics and Endocrinology Emeritus at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece and as Director of University Research Institute of Maternal And Child Health & Precision Medicine.
He currently also holds the UNESCO Chair on Adolescent Health Care. He is one of the 250 most cited scientists internationally (ISI highly cited), included not only in the list of Clinical Medicine, but also in that of Biology and Biochemistry, and is the highest cited Clinical Pediatrician or Endocrinologist in the world.
Professor Charalambos Gogos an internist and infectious diseases consultant.
He went through all the levels of hierarchy at the University of Patras where he is since 2004 Professor of Internal Medicine and Infectious Diseases.
From 2011 to 2020 he served as chairman of the Department of Internal Medicine and of Infectious Diseases of the Rion University Hospital of the University of Patras.
His main research interests are the pathophysiology of sepsis with emphasis on the immunoparalysis of sepsis and the management of chronic hepatitis C.
He has 252 publications in peer-reviewed international journals and h-index 31. Ηe is the coordinator of the Hellenic Sepsis Study Group since 2006.
George Vassiliou is a Greek Cypriot graduated from the Royal London Hospital Medical College in 1994.He is Professor of Haematological Medicine, University of Cambridge.
He is also CR-UK Senior Clinical Fellow and a member of Faculty at the Wellcome Sanger and Wellcome-MRC Cambridge Stem Cell Institutes. His group is studying the pre-clinical evolution, pathogenesis and treatment of haematological malignancies with a particular focus on acute myeloid leukaemia (AML).
He is also a Consultant Haematologist at Addenbrooke’s Hospital in Cambridge where he treats patients with haematological cancers.
Dr. Constantine E. Passaris is a Professor of Economics at the University of New Brunswick (Canada), an Onassis Foundation Fellow (Greece), a Dobbin Scholar (Ireland), a Research Affiliate of the Prentice Institute for Global Population & Economy at the University of Lethbridge (Canada), an Affiliate Member of the Canadian Institute of Cybersecurity (Canada), and a member of the Academic Scientific Board of the International Institute of Advanced Economic and Social Studies (Italy).
He has written extensively on economic issues dealing with public policy, globalization, internetization, economic governance, regional development, human rights, demography, immigration, and multiculturalism.
He has served as a member of the Economic Council of Canada, Chairman of the New Brunswick Human Rights Commission, Chairman of the Board of Directors of the Atlantic Human Rights Center at Saint Thomas University (Canada), Chairman of the New Brunswick Advisory Board on Population Growth, a member of the New Brunswick Immigration Advisory Committee and as an advisor to the Canadian Commission for UNESCO.
Dr. Panteli Theocharous is Global Vice President, Cell and Gene therapy strategy lead at PPD.
As a senior-level industry executive in prior CMO roles and a cancer immunotherapy expert, he has led multiple hematology/oncology assets in clinical development
including innovative immuno-oncology technologies and successful life cycle management, MAA/NDA and HTA submissions.
Leader in delivering transformational patient-centric solutions that prolong and improve cancer patient lives. Executive-level Client Consultation and a non-executive director (NED).